novel transcript, antisense to SMAD7

Novel transcript, antisense to SMAD7" (ENSG00000299449) is a long non-coding RNA transcript expressed from the opposite DNA strand of the SMAD7 gene. Antisense lncRNAs like this can regulate the expression of adjacent or overlapping genes, such as SMAD7, potentially through chromatin modification, transcriptional interference, or RNA–RNA interactions. Research in model systems and genome-wide studies demonstrates that antisense transcription can alter the chromatin environment, decrease the rate of sense transcript (here, SMAD7 mRNA) production and processing, and increase transcript stability, though the effects on SMAD7-specific antisense transcripts in human health and disease are not well-characterized. There is no evidence that this transcript is itself a protein, enzyme, receptor, transporter, or bona fide drug target in the traditional sense. Antisense transcription is a widespread phenomenon across the human genome, often impacting the expression levels and stability of protein-coding "sense" transcripts. SMAD7 itself is a well-studied protein-coding gene involved in TGF-β signaling, cancer, inflammation, and fibrosis, but its antisense lncRNA's functions are less clear and remain under investigation. The entry "novel transcript, antisense to SMAD7" is not a canonical therapeutic target, receptor, transporter, or enzyme. It should not be confused with SMAD7 protein. This target is not a protein or a typical drug target but a long non-coding antisense RNA presumed to modulate SMAD7 gene transcription. It is not considered a classical therapeutic target, and there are currently no drugs known to interact with this molecule, nor is it established as a biomarker or disease target.

Other names

antisense RNA to SMAD7SMAD7-ASENSG00000299449